Children longitudinal cohort | Children cross-sectional cohort | Adults retrospective cohort | |
Patients (n) | 40 | 64 | 49 |
Sex, n (%) | |||
Female | 17 (42.5) | 23 (36) | 18 (36.7) |
Male | 20 (57.5) | 41 (64) | 31 (63.3) |
Age, mean years (range) | 9.4 (0.75–16) | 7 (0.9–17.8) | 44.4 (17–65.8) |
Primary disease, n (%) | |||
ALL | 23 (57.5) | 25 (39.1) | 6 (12.2) |
AML | 11 (27.5) | 11 (17.2) | 19 (38.8) |
JMML | 3 (7.5) | 2 (3.1) | – |
NHL | 1 (2.5) | 1 (1.6) | 13 (26.5) |
MDS | 1 (2.5) | 2 (3.1) | 5 (10.2) |
CML | 1 (2.5) | 3 (4.7) | 2 (4.1) |
Others | – | 20 (31.2) | 4 (8.2) |
Donor, n (%) | |||
MSD | 19 (47.5) | 32 (50) | 49 (100%) |
MUD | 21 (52.5) | 32 (50) | – |
Stem cell sources, n (%) | |||
Peripheral blood | – | – | 30 (61.2) |
Bone marrow | 40 (100) | 64 (100) | 19 (38.8) |
Conditioning, n (%) | |||
MA | 40 (100) | 64 (100) | 24 (49) |
NMA | – | – | 25 (51) |
In vivo T-cell depletion, n (%) | 12 (30) | 18 (28) | 20 (40.8) |
Acute GVHD | |||
Grades 1–2 | 24 (60) | NA | |
Grades 3–4 | 9 (22.5) | NA | 4 (8.2) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphoblastic leukemia; CML, chronic myeloid leukemia; JMML, juvenile myelomonocytic leukemia ; MDS, myelodysplasic syndrome ; MSD, matched sibling donor; MUD, matched unrelated donor; NHL, non-Hodgkin's lymphoma.